+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Acne Vulgaris - Pipeline Review, H1 2020

  • ID: 5024749
  • Drug Pipelines
  • April 2020
  • Region: Global
  • 224 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Allianz Pharmascience Ltd
  • Cassiopea SpA
  • Devonian Health Group Inc
  • Kalytera Therapeutics Inc
  • Novartis AG
  • Revive Therapeutics Ltd
  • MORE
Acne Vulgaris - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Acne Vulgaris - Pipeline Review, H1 2020, provides an overview of the Acne Vulgaris (Dermatology) pipeline landscape.

Acne vulgaris is a chronic skin disease involving blockage and inflammation of pilosebaceous follicles. Symptoms include crusting of skin bumps, cysts, papules (small red bumps), scarring of the skin and redness around the skin eruptions. Risk factors include adolescence, hair gels or oil-based cosmetics, sports equipment such as helmet straps rubbing and occluding skin. Treatment includes antibiotics.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Acne Vulgaris - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Acne Vulgaris (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acne Vulgaris (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Acne Vulgaris and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 10, 20, 4, 1, 13, 6 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.

Acne Vulgaris (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acne Vulgaris (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Acne Vulgaris (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acne Vulgaris (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acne Vulgaris (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acne Vulgaris (Dermatology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acne Vulgaris (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acne Vulgaris (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Allianz Pharmascience Ltd
  • Cassiopea SpA
  • Devonian Health Group Inc
  • Kalytera Therapeutics Inc
  • Novartis AG
  • Revive Therapeutics Ltd
  • MORE
  • Introduction
  • Acne Vulgaris - Overview
  • Acne Vulgaris - Therapeutics Development
  • Acne Vulgaris - Therapeutics Assessment
  • Acne Vulgaris - Companies Involved in Therapeutics Development
  • Acne Vulgaris - Drug Profiles
  • Acne Vulgaris - Dormant Projects
  • Acne Vulgaris - Discontinued Products
  • Acne Vulgaris - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Acne Vulgaris, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Acne Vulgaris - Pipeline by Allianz Pharmascience Ltd, H1 2020
  • Acne Vulgaris - Pipeline by Amgen Inc, H1 2020
  • Acne Vulgaris - Pipeline by AOBiome LLC, H1 2020
  • Acne Vulgaris - Pipeline by Avecho Biotechnology Ltd, H1 2020
  • Acne Vulgaris - Pipeline by Bausch Health Companies Inc, H1 2020
  • Acne Vulgaris - Pipeline by Biomimetix JV LLC, H1 2020
  • Acne Vulgaris - Pipeline by BioPharmX Inc, H1 2020
  • Acne Vulgaris - Pipeline by Boston Pharmaceuticals Inc, H1 2020
  • Acne Vulgaris - Pipeline by Botanix Pharmaceuticals Ltd, H1 2020
  • Acne Vulgaris - Pipeline by Boulos and Cooper Pharmaceuticals Pty Ltd, H1 2020
  • Acne Vulgaris - Pipeline by Cassiopea SpA, H1 2020
  • Acne Vulgaris - Pipeline by Cellix Bio Pvt Ltd, H1 2020
  • Acne Vulgaris - Pipeline by Cutanea Life Sciences Inc, H1 2020
  • Acne Vulgaris - Pipeline by Daewoong Co Ltd, H1 2020
  • Acne Vulgaris - Pipeline by Dermata Therapeutics LLC, H1 2020
  • Acne Vulgaris - Pipeline by Dermavant Sciences Inc, H1 2020
  • Acne Vulgaris - Pipeline by Devonian Health Group Inc, H1 2020
  • Acne Vulgaris - Pipeline by Eligo Bioscience SA, H1 2020
  • Acne Vulgaris - Pipeline by ELORAC Inc, H1 2020
  • Acne Vulgaris - Pipeline by Gage Development Company LLC, H1 2020
  • Acne Vulgaris - Pipeline by Galderma SA, H1 2020
  • Acne Vulgaris - Pipeline by Helix BioMedix Inc, H1 2020
  • Acne Vulgaris - Pipeline by Innovation Pharmaceuticals Inc, H1 2020
  • Acne Vulgaris - Pipeline by Johnson & Johnson, H1 2020
  • Acne Vulgaris - Pipeline by Kalytera Therapeutics Inc, H1 2020
  • Acne Vulgaris - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2020
  • Acne Vulgaris - Pipeline by Melinta Therapeutics Inc, H1 2020
  • Acne Vulgaris - Pipeline by Menlo Therapeutics Inc, H1 2020
  • Acne Vulgaris - Pipeline by Mimetica Pty Ltd, H1 2020
  • Acne Vulgaris - Pipeline by Naked Biome Inc, H1 2020
  • Acne Vulgaris - Pipeline by Novabiotics Ltd, H1 2020
  • Acne Vulgaris - Pipeline by Novartis AG, H1 2020
  • Acne Vulgaris - Pipeline by Origimm Biotechnology GmbH, H1 2020
  • Acne Vulgaris - Pipeline by Ortho Dermatologics Inc, H1 2020
  • Acne Vulgaris - Pipeline by Phagelux Inc, H1 2020
  • Acne Vulgaris - Pipeline by PHI Therapeutics Inc, H1 2020
  • Acne Vulgaris - Pipeline by Photocure ASA, H1 2020
  • Acne Vulgaris - Pipeline by Promius Pharma LLC, H1 2020
  • Acne Vulgaris - Pipeline by Provectus Biopharmaceuticals Inc, H1 2020
  • Acne Vulgaris - Pipeline by Revive Therapeutics Ltd, H1 2020
  • Acne Vulgaris - Pipeline by Riptide Bioscience Inc, H1 2020
  • Acne Vulgaris - Pipeline by Sanotize Research And Development Corp, H1 2020
  • Acne Vulgaris - Pipeline by Sebela Pharmaceuticals Inc, H1 2020
  • Acne Vulgaris - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2020
  • Acne Vulgaris - Pipeline by Sol-Gel Technologies Ltd, H1 2020
  • Acne Vulgaris - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2020
  • Acne Vulgaris - Pipeline by Union Therapeutics AS, H1 2020
  • Acne Vulgaris - Pipeline by Verge Therapeutics Inc, H1 2020
  • Acne Vulgaris - Pipeline by Vyome Therapeutics Inc, H1 2020
  • Acne Vulgaris - Dormant Projects, H1 2020
  • Acne Vulgaris - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Acne Vulgaris - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Acne Vulgaris - Dormant Projects, H1 2020 (Contd..3), H1 2020
  • Acne Vulgaris - Dormant Projects, H1 2020 (Contd..4), H1 2020
  • Acne Vulgaris - Dormant Projects, H1 2020 (Contd..5), H1 2020
  • Acne Vulgaris - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Acne Vulgaris, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Allianz Pharmascience Ltd
  • Amgen Inc
  • AOBiome LLC
  • Avecho Biotechnology Ltd
  • Bausch Health Companies Inc
  • Biomimetix JV LLC
  • BioPharmX Inc
  • Boston Pharmaceuticals Inc
  • Botanix Pharmaceuticals Ltd
  • Boulos and Cooper Pharmaceuticals Pty Ltd
  • Cassiopea SpA
  • Cellix Bio Pvt Ltd
  • Cutanea Life Sciences Inc
  • Daewoong Co Ltd
  • Dermata Therapeutics LLC
  • Dermavant Sciences Inc
  • Devonian Health Group Inc
  • Eligo Bioscience SA
  • ELORAC Inc
  • Gage Development Company LLC
  • Galderma SA
  • Helix BioMedix Inc
  • Innovation Pharmaceuticals Inc
  • Johnson & Johnson
  • Kalytera Therapeutics Inc
  • Lee's Pharmaceutical Holdings Ltd
  • Melinta Therapeutics Inc
  • Menlo Therapeutics Inc
  • Mimetica Pty Ltd
  • Naked Biome Inc
  • Novabiotics Ltd
  • Novartis AG
  • Origimm Biotechnology GmbH
  • Ortho Dermatologics Inc
  • Phagelux Inc
  • PHI Therapeutics Inc
  • Photocure ASA
  • Promius Pharma LLC
  • Provectus Biopharmaceuticals Inc
  • Revive Therapeutics Ltd
  • Riptide Bioscience Inc
  • Sanotize Research And Development Corp
  • Sebela Pharmaceuticals Inc
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • Sol-Gel Technologies Ltd
  • Sun Pharma Advanced Research Company Ltd
  • Union Therapeutics AS
  • Verge Therapeutics Inc
  • Vyome Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll